FDA will reconsider decision barring copycat versions of Lilly weight loss drug
The Food and Drug Administration (FDA) said it will reconsider its decision to remove Eli Lilly’s blockbuster weight loss and diabetes drug from its official shortage list and allow compounding pharmacies to continue selling their own versions.
A federal court in Texas on Friday granted the FDA’s unopposed motion to stay litigation over the drug’s removal from shortage.
In a court filing late Friday, the FDA said it wouldn’t pursue regulatory action against the plaintiff compounding pharmacies for making copies of the drugs while it reconsiders the decision.
The FDA’s motion marked a significant reversal for the agency, which was sued last week by compounding pharmacies and a trade organization representing compounding pharmacies after removing tirzepatide from the shortage list.
At the time, the agency said removing the drug meant compounding pharmacies would no longer be legally allowed to continue making and dispensing their own versions.
In the lawsuit, the Outsourcing Facilities Association claimed the drug was still in short supply, and that the agency’s decision was “reckless and arbitrary.” The group asked a federal court in Texas to issue a 14-day temporary restraining order that would prevent the FDA from taking action against any of the plaintiffs for continuing to make copies of the drug.
Tirzepatide is sold as Mounjaro for diabetes and Zepbound for obesity.
In a statement to The Hill, a spokesperson for Lilly said all doses of Mounjaro and Zepbound are available and reiterated the branded drug industry’s view that compounded versions are risky for patients.
“All doses of Lilly’s FDA-approved medicines are available and it is important that patients not be exposed to the risks in taking untested, unapproved knockoffs,” the spokesperson said.
"FDA has rightly and repeatedly expressed concerns with unapproved GLP-1 drugs used for weight loss, and that such drugs are risky for patients, as unapproved versions do not undergo FDA’s review for safety, effectiveness and quality before they are marketed.”
Compounded anti-obesity drugs are sold at vastly lower prices than the branded versions and can give patients needed access to drugs that are in shortage. The lawsuit argued the FDA was taking away that access.
In the motion, the FDA asked the court to pause the lawsuit and remand the case back to the agency, which would allow it to “reevaluate the decision in light of Plaintiffs’ challenges to it.”
The agency said it would not take action against the compounders while it reconsiders, “which is effectively the relief that plaintiffs sought.”
The agency asked the plaintiffs to “submit additional information regarding tirzepatide’s availability” while it reconsiders.
U.S. District Judge Mark Pittman in Fort Worth, Texas, granted the motion and put the lawsuit on hold. A joint status report is due Nov. 21.
The FDA said its enforcement discretion will extend from the date of the order to two weeks beyond its reconsideration of the decision.
In a statement, Outsourcing Facilities Association chair Lee Rosebush called the move a “fair resolution” and said the group is “greatly relieved, for our members and the many patients that they serve, that the FDA has agreed to reconsider its decision."
He added that “should the FDA repeat its removal decision when a shortage still genuinely exists, we will return to court.”
Date: |
-
Top stories - NBC News
Compounding pharmacies can resume making tirzepatide as FDA reconsiders shortage
The FDA said in a court filing late Friday that it would allow pharmacists to continue making compounded versions of tirzepatide as it reconsiders whether the drug is in shortage.3 hours ago -
World - The Guardian
Elon Musk was not barred from UK investment summit, says cabinet minister
SpaceX owner would be invited in future if he had investment streams the UK could bid for, says Peter Kyle. Elon Musk would be welcome at future UK investment summits if and when he had investment ...15 hours ago - United Kingdom -
Top stories - CBS News
Costco's gold bars are selling out. Here's where else to buy them.
If you're planning to buy gold at Costco's warehouse stores, you may need a backup plan. Here's where else to look.6 hours ago -
Lifestyle - The New York Times
Reconsidering the Hollywood Reporter’s A-List of Influencers
A social media post about the Hollywood Reporter’s “A-List” of influencers inspired quite a few jokes online. But part of that was a misunderstanding.2 days ago
More from The Hill
-
Politics - The Hill
Robinson lashes out at Republican senator amid tensions over campaign
North Carolina GOP gubernatorial nominee Mark Robinson recently lashed out at Sen. Thom Tillis (R-N.C.) at a campaign event, slamming the senior senator as “spineless” following tensions ...1 hour ago -
Politics - The Hill
What to know about US defense system heading to Israel
Welcome to The Hill's Defense & NatSec newsletter {beacon} Defense &National Security Defense &National Security The Big Story What to know about the prized US air defense system heading to ...1 hour ago - Israel -
Politics - The Hill
What to know about California's controversial new law aimed at preventing gas price spikes
California Gov. Gavin Newsom (D) on Monday signed into law a controversial slate of plans to tighten fuel refinery storage rules in an effort to prevent future fuel shortages and price spikes at ...2 hours ago - California -
Politics - The Hill
Trump says national abortion ban 'off the table'
Click in for more news from The Hill {beacon} Health Care Health Care The Big Story Trump hedges on abortion ban Former President Trump said a national abortion ban is “off the table” but left ...2 hours ago - Donald Trump -
Politics - The Hill
Tackling misinformation at school
Welcome to The Hill's Technology newsletter {beacon} Technology Technology The Big Story Schools tackle false info amid hurricanes, election Schools face challenges teaching children how to ...2 hours ago